Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/12/2012WO2012093681A1 Method for selecting patient to be given drug for treating septicemia
07/12/2012WO2012093533A1 Agent for improving milk yield and/or milk quality of ruminants, preventive or therapeutic agent for perinatal disease, and agent for improving reproductive efficiency
07/12/2012WO2012093383A1 Compositions and methods for treatment of sepsis and related conditions
07/12/2012WO2012093258A2 Treatment and screening
07/12/2012WO2012093255A1 Use of the phytocannabinoid cannabidiol (cbd) in combination with a standard anti-epileptic drug (saed) in the treatment of epilepsy
07/12/2012WO2012093252A1 Pharmaceutical composition
07/12/2012WO2012093234A2 Sulphated arabinogalactans, apiogalacturonans and sulphated heteroglycans for treating diseases caused by the influenza virus
07/12/2012WO2012093227A1 Prodrugs for dispensing a statin to the liver
07/12/2012WO2012093192A1 Coly-mycin derivatives
07/12/2012WO2012093171A1 Method for preparing aqueous pharmaceutical suspensions including a drug that is effective in treating rhinitis
07/12/2012WO2012093169A1 Novel sulfamide piperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
07/12/2012WO2012093161A1 Immunosuppressant formulations
07/12/2012WO2012093148A1 Fused aminodihydrothiazine derivatives
07/12/2012WO2012093137A1 Liposome formulation suitable for treating or preventing tuberculosis
07/12/2012WO2012093117A1 Methods and pharmaceutical compositions for the treatment of ocular inflammatory diseases
07/12/2012WO2012093109A1 Pyrrolidine derivatives as nk3 antagonists
07/12/2012WO2012093101A1 Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)
07/12/2012WO2012093100A1 Pyrazol-4-yl carboxamide derivatives as microbiocides
07/12/2012WO2012093091A2 New saccharide mimics and their use as inhibitors of angiogenesis and metastasis formation
07/12/2012WO2012093087A1 Hypotonic aqueous composition with reduced chloride content, with or without phospholipids
07/12/2012WO2012092880A1 2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINE DERIVATIVES AS FAK/Pyk2 INHIBITORS
07/12/2012WO2012092712A1 Lyophilized nanometer particle powder preparation comprising recombinant albumin prepared from human plasma
07/12/2012WO2012068516A3 Low dose cannabinoid medicaments
07/12/2012WO2012068454A3 Nrf2 deficiency influences susceptibility to steroid resistance via hdac2 reduction
07/12/2012WO2012068381A9 Protection of renal tissues from schema through inhibition of the proliferative kisses cdk4 and cdk6
07/12/2012WO2012068340A3 Antagonat compositions and methods of use
07/12/2012WO2012068251A3 Agonists that enhance binding of integrin-expressing cells to integrin receptors
07/12/2012WO2012067447A3 Composition containing styraxlignolide a or the aglycone thereof as an active ingredient for preventing or treating asthma
07/12/2012WO2012065110A3 S-protected cysteine analogs and related compounds
07/12/2012WO2012064697A3 Materials presenting notch signaling molecules to control cell behavior
07/12/2012WO2012062925A3 Compounds and methods for treating pain
07/12/2012WO2012062917A3 Process for obtaining chondroitin sulphated at the 4- or 6- positions of n-acetyl-galactosamine residues
07/12/2012WO2012061822A9 Materials and methods for mobilizing cells including cd34+, hematopoietic colony forming, and endothelial colony forming cells
07/12/2012WO2012061360A3 Pharmaceutical compositions
07/12/2012WO2012061165A3 Methods and compositions for improving admet properties
07/12/2012WO2012061086A3 Method of treating neuroendocrine tumors
07/12/2012WO2012058241A3 Methods and compositions for ameliorating pancreatic cancer
07/12/2012WO2012058115A3 Anti-cancer serine hydrolase inhibitory carbamates
07/12/2012WO2012057492A9 Rapamycin formulation using recombinant high-density lipoprotein including apolipoprotein a-i and a mutant thereof
07/12/2012WO2012054701A3 Creatine oral supplementation using creatine hydrochloride salt
07/12/2012WO2012048214A9 Use of hyaluronan for promoting angiogenesis
07/12/2012WO2012048204A3 Prodrugs utilizing a transporter directed uptake mechanism
07/12/2012WO2012042091A3 Use of tak1 inhibitors in the prevention and treatment of peritoneal membrane failure
07/12/2012WO2012032479A8 1,5-diaryl-2-alkylpyrrole-3-substituted nitro esters, selective cox-2 inhibitors and nitric oxide donors
07/12/2012WO2012032209A3 Pharmaceutical composition for the treatment of dry eye
07/12/2012WO2012032150A3 Process for obtaining hyaluronic acid of defined molecular weight
07/12/2012WO2012030957A3 Non-hygroscopic salts of 5-ht2c agonists
07/12/2012WO2012028922A3 Controlled release pharmaceutical compositions of milnacipran
07/12/2012WO2012021791A3 Aqueous formulation with improved stability
07/12/2012WO2012009508A3 Microrna compositions and methods related thereto
07/12/2012WO2012007758A3 Pharmaceutical formulations
07/12/2012WO2012005709A3 Pharmaceutical composition comprising valsartan
07/12/2012WO2011154724A3 Injectable flowable composition comprising buprenorphine
07/12/2012WO2011149877A8 Intestinal brake inducing intraluminal therapeutic substance eluting devices and methods
07/12/2012WO2011060290A8 Immediate release tablet formulations
07/12/2012WO2011049706A8 Orally transformable tablets
07/12/2012WO2007079840A9 Benzochromene derivatives
07/12/2012US20120180147 Microrna-24
07/12/2012US20120178821 Polymorphic form of toremifene citrate and process for its preparation
07/12/2012US20120178820 Method for treating arthritis
07/12/2012US20120178819 Selective, Lipophilic, and Long-Acting Beta Agonist Monotherapeutic Formulations and Methods for the Cosmetic Treatment of Adiposity and Contour Bulging
07/12/2012US20120178816 Carbamide peroxide treatments for the reproductive tract
07/12/2012US20120178815 Compositions of (-)-E-10-OH-NT and Methods for Their Synthesis and Use
07/12/2012US20120178814 Biphenyloxyacetic Acid Derivatives for the Treatment of Respiratory Disease
07/12/2012US20120178813 Lipid-lowering antidiabetic agent
07/12/2012US20120178812 Pharmaceutical Formulations Containing Lipoic Acid Derivatives
07/12/2012US20120178811 Method of using beta-hydroxy-beta-methylbutyrate to reduce the risk of infection in an elderly individual
07/12/2012US20120178810 Extended release formulation of an antiepileptic agent
07/12/2012US20120178809 Salt of Dimethylaminomethyl-Phenyl-Cyclohexane and Crystalline Forms Thereof
07/12/2012US20120178808 Formulation comprising fenofibric acid, a physiologically acceptable salt or derivative thereof
07/12/2012US20120178806 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle
07/12/2012US20120178805 Phenolic hydrazone macrophage migration inhibitory factor inhibitors
07/12/2012US20120178803 Method for treating brain cancer or reducing temozolomide-resistance of brain cancer cells
07/12/2012US20120178802 2,3-Fluorinated Glycosides as Neuraminidase Inhibitors and Their Use as Anti-Virals
07/12/2012US20120178801 Compositions and its use in treating obesity or inducing weight loss
07/12/2012US20120178799 Energy beverage with creatine and caffeine combination
07/12/2012US20120178798 Substituted cyclopentanes having prostaglandin activity
07/12/2012US20120178797 Novel therapeutic and diagnostic products and methods
07/12/2012US20120178796 Splice variants
07/12/2012US20120178795 Rnai-mediated inhibition of frizzled related protein-1 for treatment of glaucoma
07/12/2012US20120178794 RNAi-Mediated Inhibition of RHO Kinase for Treatment of Ocular Disorders
07/12/2012US20120178793 Nucleotide-cochleate compositions and methods of use
07/12/2012US20120178792 Drg11-responsive (dragon) gene family
07/12/2012US20120178791 MODULATION OF HUMAN CYTOMEGALOVIRUS REPLICATION BY MICRO-RNA 132 (miR132), MICRO-RNA 145 (miR145) AND MICRO-RNA 212 (miR212)
07/12/2012US20120178790 Crystalline form of a 3-phenoxymethylpyrrolidine compound
07/12/2012US20120178789 Novel pyrrolidines as glucagon receptor antagonists, compositions, and methods for their use
07/12/2012US20120178788 Method for suppressing esterification of pharmaceutical composition
07/12/2012US20120178787 Melatonin and its use in preventing postoperative complications
07/12/2012US20120178785 Derivatives of n-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators
07/12/2012US20120178784 Use Of Inhibitors Of The Renin-Angiotensin System
07/12/2012US20120178783 Hdac inhibitors
07/12/2012US20120178782 Compositions and methods for treating proliferative diseases
07/12/2012US20120178781 Kappa opioid receptor ligands
07/12/2012US20120178780 Raf kinase inhibitors
07/12/2012US20120178778 Pyrazolopyridines
07/12/2012US20120178777 Medicaments for Inhibiting Thrombus Formation
07/12/2012US20120178776 Dihydronaphthyridinyl(organo)methanone analogs as positive allosteric mglur5 modulators
07/12/2012US20120178775 Methods for treating frontotemporal lobar degeneration with ubiquitinated inclusions (ftld-u)
07/12/2012US20120178774 Toll-like receptor modulators and uses thereof
07/12/2012US20120178773 Compositions Comprising Enzyme-Cleavable Oxycodone Prodrug
1 ... 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 ... 7860